CD44 and obesity due to melanocortin 4 receptor deficiency: CD44-targeted therapies show promise for treating metabolic diseases such as obesity and diabetes, with development currently underway at the preclinical stage.21 Thus, CD44 plays a pivotal role as a signaling regulator in maintaining stemness, allowing CD44-positive cells to resist standard drug treatments and drive recurrence and metastasis.